Farallon Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Farallon Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,000	Closed	-$232K	–	197
2025 Q4	$232K	Sell	5,000 -148,000	-97%	-$8.11M	﹤0.01%	126
2025 Q3	$10.3M	Buy	153,000 +148,000	+2,960%	+$11M	0.04%	75
2025 Q2	$419K	Hold	5,000	–	–	﹤0.01%	93
2025 Q1	$357K	Sell	5,000 -85,000	-94%	-$4.14M	﹤0.01%	102
2024 Q4	$4.05M	Buy	+90,000	New	+$4.66M	0.02%	88
2024 Q2	–	Sell	-27,750	Closed	-$1.19M	–	182
2024 Q1	$1.19M	Sell	27,750 -137,469	-83%	-$6.22M	0.01%	120
2023 Q4	$6.65M	Sell	165,219 -222,781	-57%	-$6.34M	0.03%	87
2023 Q3	$11.4M	Buy	+388,000	New	+$2.35M	0.05%	84

Other funds holding SLNO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Farallon Capital Management's SLNO Position: Q1 2026 in Review

Farallon Capital Management sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 5,000 shares — an estimated $232K sold.

Farallon Capital Management first reported a position in SLNO in Q3 2023 and held it in 8 quarters. The position peaked at $11.4M in Q3 2023. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

Farallon Capital Management reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
Farallon Capital Management sold 5,000 Soleno Therapeutics shares in Q1 2026, an estimated $232K.
Farallon Capital Management first reported a position in Soleno Therapeutics in Q3 2023 and held it in 8 quarters.
Farallon Capital Management's Soleno Therapeutics position peaked at $11.4M in Q3 2023.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.